

Pathology of noninfectious vasculitides

Eva Honsova

Institute for Clinical and Experimental Medicine
Prague, Czech Republic

eva.honsova@ikem.cz

Systemic noninfectious vasculitides


Vasculitis = a general term for inflammation of vessel walls

Any type of vessel in all locations can be affected in practice – overwhelming number of clinical symptoms and problems


- **Clinical manifestation:** *very variable, the disease has attacks and spontaneous remissions*
- *the diagnosis is difficult*

The vasculitides are often serious diseases, prompt recognition and therapy.

Patients suffer from **symptoms of systemic inflammation** (such as fever, arthralgias, myalgias, weight loss), and can simultaneously have **symptoms of local system involvement**. They can develop **local mass lesion** which can lead to the diagnosis of malignant tumor




nodulus imitatus metastasis



Historical development of names of vasculitides

1. description of necrotizing arteritis (PAN) Rokitanský (1852)

Periarteritis nodosa (1866 Kussmaul, Maler)



For decades PAN was the term used for virtually any patient with necrotizing arteritis

First description of necrotizing arteritis with aneurysmata (PAN, 1852)

Karel Rokitanský



- Karel Rokitanský was born in Hradec Králové, started his medicine study in Prague under Purkyně.
- When Purkyně left in r. 1823 for Wroclaw Rokitanský went to Vienna.
- Aneurysmal lesions in numerous arteries in a 23-year-old shoemaker (without histology)
- Eppinger: *histological* confirmation
- 1866; Kussmaul and Maier: 27-year-old tailor; ***periarteritis nodosa*** with histology (with the involvement of gli)

Death of colleague Dr. Koletscko, who succumbed the sepsis after injury at autopsy room, has inspired Dr. Ignaz Semmelweis (a pioneer in antiseptic medical practice).



Karl, baron von Rokitansky

Austrian pathologist

Written by: The Editors of Encyclopædia Britannica



Karl, baron von Rokitansky, (born Feb. 19, 1804, Königgrätz, [Austria](#)—died July 23, 1878, [Vienna](#)), Austrian pathologist whose endeavours to establish a systematic picture of the sick organism from nearly 100,000 autopsies—30,000 of which he himself performed—helped make the study of pathological [anatomy](#) a cornerstone of modern medical practice and established the New Vienna School as a world medical centre during the latter half of the 19th century.

A professor of pathological anatomy (1844–74) at the Vienna General Hospital, he inspired the Bohemian student Ignaz [Semmelweis](#), later a martyr to the cause of antiseptic medical practice, to take up the study of [medicine](#) (1846) and afterward supported him in his struggle to eliminate childbed fever by cleaning up Europe's maternity wards.

First to detect bacteria in lesions of malignant [endocarditis](#), an often rapidly fatal inflammation of the [membrane](#) lining the inner walls of the [heart](#), Rokitansky created the basis for a differentiation of lobar [pneumonia](#) (originating in the lower lobe of the lung) and lobular pneumonia, or bronchopneumonia (originating in the finer subdivisions of the branched bronchial tree). He made a fundamental study of acute yellow atrophy of the [liver](#) (now known as Rokitansky's disease; 1843), established the micropathology of pulmonary [emphysema](#) (a condition of the [lung](#) characterized by


Karl, baron von Rokitansky



Rokitansky, detail of an engraving

BBC Hulton Picture Library

2012 revised international CHCC nomenclature of vasculitides



Nomenclature noninfectious vasculitides

1. Large vessel vasculitis: GCA a Takayasu

2. Medium vessel vasculitis: PAN a Kawasaki

3. Small vessel vasculitis (arteries, arterioles, venules, veins):

a) ANCA-associated vasculitis (most frequent vasculitis of adults!!!)

b) immune complex:

IgA v.(Henoch-Schönlein), anti-GBM (ANCA : anti-GBM = 100 : 1), cryoglobulins, hypocomplementic urticarial (anti-C1q) v., serum sickness

4.

Variable vessel vasculitis (Cogan's, Behcet's, etc.)

Single organ vasculitis (cutaneous SVV, primary CNS vasculitis, etc.)

Vasculitis associated with systemic diseases (e.g. Rheumatoid, Lupus, Sarcoid, etc.)

Vasculitis associated with probable etiologies (e.g. HBV, HCV, drug, cancer, etc.)


Large Vessel Vasculitis, 2012 CHCC definition

Vasculitis *affecting large arteries more often than other vasculitides*. Large arteries are the aorta and its major branches. Any size artery may be affected.

1. Takayasu arteritis

Patients: **women under 50**, rare in the Czech Rep.


- **Morphology**: shares histological features of GCA (granulomatous arteritis), *no fibrinoid necrosis*



2. Giant cell (temporal) arteritis (GCA)

- Patients: **over 50**, common (with polymyalgia rheumatica)




The distinction between the two entities is made on the basis of a patient's age!!!



PAN, 2012 CHCC definition




- Necrotizing arteritis of medium or small arteries ***without glomerulonephritis*** or vasculitis in arterioles, capillaries, or venules; and ***not associated with ANCA***.

- Very rare



Kawasaki disease; 2012 CHCC definition


- Arteritis associated with *the mucocutaneous lymph node syndrome*, predominantly affecting medium and small arteries.
- *Coronary arteries are often involved*. Aorta and large arteries may be involved.
- Usually occurs in infants and young children.



Small vessel vasculitides




1. ANCA-associated small vessel v.

- GPA (Wegener g.)
- MPA (microscopic polyangitis)
- EGPA (Churg-Strauss sy)




2. Immune complex small vessel v.

- Anti-GBM
- IgA v. (HSP)
- Cryoglobulinemic v.
- Hypocomplementemic urticarial v.



ANCA antibodies (Anti-Neutrophil Cytoplasmic Antibody)

- ABs specific to antigens of neutrophil granules and to lysosomes of monocytes;
- **c-ANCA** (cytoplasmatic) **p-ANCA**(perinuclear)
- **Many different antigens in the group c- or p- (*proteinasa 3, myeloperoxidasa-MPO, lactoferin, cathepsin G, elastasa, lysosym, azurocidin atd.*)**
- **ANCA positive vasculitides:**



c-ANCA: PR3 (proteinasa 3),

p-ANCA: MPO (myeloperoxidasa)


IF determine the group c or p

ELISA distinguishes the precise antigens

(PR3 or MPO) which are associated with AAV

- New methods for identification of specific epitopes (MALDI-TOF/TOF-MALDI-MS)
Epitope specificity defines pathogenicity

(Roth A. at al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013; 123:1773-1783.)



ANCA associated vasculitis:

- very aggressive disease; systemic involvement (joints, skin, ENT, lungs, kidneys)
 - May occur at any age, typical onset between 5th-7th decades of life
 - **The most common form of systemic vasculitis in adulthood**
 - Estimated incidence **>15-23/million**
age over **65: 53/million**
 - Geographical variation: *c ANCA more frequent in northern Europe, p ANCA more frequent in southern Europe, Asia and Japan*
- Prognosis of untreated** GPA (c ANCA) is worse than the prognosis of the majority of tumors; and the **mortality rate at 1 year is 80%**
- Rapid dg is critical***

Occurrence of systemic involvement

(Jennette J. N. Eng J Med: 1997; 337:1512-1523).




location	HSP	cryoglob	MPA	GPA	EGPA
skin	90%	90%	60%	50 - 70%	60%
kidney	50%	55%	90%	80%	45%
lung	<5%	<5%	50%	90%	70%
ENT	<5%	<5%	35%	90%	50%
joint	75%	70%	60%	60%	50%
neurol.	10%	40%	30%	50%	70%
GIT	60%	30%	30%	50%	50%

The concept that MPO- and PR3-AAV are genetically distinct diseases with phenotypic overlap and that studies and clinical practice may ***benefit from clustering according to serotype***.

Lyons P. A. et al. Genetically distinct subset within ANCA-associated vasculitis. N.Engl. J. Med. 2012; 367: 214-223.

ANCA-associated vasculitides

- Any organ may be afflicted (kidney, lungs, ENT...)
- Kidney involvement:
pauciimmune necrotizing crescentic
(rapidly progressive) glomerulonephritis
75% of patients with GN have systemic vasculitis
- Renal biopsy:
 - Gold standard to confirm the diagnosis
 - To assess the prognosis
 - Not absolutely required,
but recommended whenever possible








ANCA-associated GN: morphology: gli

pauciimmune necrotizing GN with crescents








Acute lesions: necrosis + crescents

Typically scattered with normal glomeruli or their parts, later with combination of acute and chronic lesions




ANCA-associated GN: morphology: gli

Crescents: epithelial/cellular, fibro-epithelial, fibrotic








ANCA-associated GN:morphology








vessels & interstitium



ANCA-associated GN: morphology of advanced disease



Time period during the course of vasculitis in morphology



When it is difficult to diagnosed AAV

In a kidney biopsy:


- Early acute lesion: normal morphology; sampling error
- Advanced lesion (destruction and high number of crescents)
- Chronic scarring lesions
- Combinations: with IgA and or other diseases (modify the morphological features); anti-GBM, DM, SLE: mainly MPA with slow progression with segmental sclerotic lesions

In other locations/organs:

- More difficult to diagnose vasculitis (often second opinion can help)

Case no. 1.: 63-year-old woman




- *Autumn 2002* worse hearing, ENT in normal range, CT showed inflammation in the middle ear
- She visited internist in *January* next year
- She requested lungs examination, normal
- *February*: artralgi~~a~~s of small joints, susp.
- *May*: S-Cr 197 $\mu\text{mol/l}$, microhematurie
- *June*: S-Cr 273 $\mu\text{mol/l}$;
- only then she is sent to nephrologist
- Weight loss: 6 kg



AAV advanced morphological features (MPA, p-ANCA)

Case no. 2.: a 25-year-old woman

- During the last year: **recurrent otitis media** and sinusitis
- 5 weeks she is not feeling well, fever
- Admitted to the hospital at pulmonary department
- Dg.: **pulmonary infiltrates, fever**
- **c-ANCA +++**, treated with ATB
- S-Cr 143 $\mu\text{mol/l}$ (1.61mg/dl)
- urine: numerous ery




Successful treatment, S-Cr 90 $\mu\text{mol/l}$, PU less than 1g/day, after 5 years: a healthy child
Now, 14 years after renal manifestation, during 2 last years: relapse in ENT and lungs location


Case no. 3.: 28-year-old man

- 5 mths of *non-specific symptoms*: myalgia, artralgia, unintended weight loss (10 kg)
- *chronic otitis media* with hypacusis l. sin.
acute polyneuropathy: hypoesthesia and paresthesia
- mild hematuria and proterinuria (1 g/day), sterile pyuria
- CRP 45 mg/dl, sCr 120 μ mol/l; 1.36 mg/dl, Hb 99
- US and CT: ***mass of left kidney*** – exploratory surgery
- firm and whitish appearance;
- perioperative biopsy – **no malignant cells, granulomatous inflammation**
- mass seemed malignant – nephrectomy completed


Case no. 3.: nephrectomy specimen






Case no. 3.: nephrectomy specimen



Case no. 3.: nephrectomy specimen



Case no. 3.: nephrectomy specimen





Case no. 3.


- diagnosis of **granulomatosis with polyangiitis** confirmed by c-ANCA positive (IF and ELISA)
- treated with corticoids and cyclophosphamide until complete recovery
- remission in the ***follow-up (14 years) – normal renal function*** (S-Cr 76 μ mol/l; 0.86 mg/dl), ANCA negative, only mild proteinuria (0.6 g/day)
- maintenance therapy – low-dose azathioprine

AAV, systemic involvement



nodulus imitatus metastasis



stomach



skin



Czech Registry of ANCA-associated vasculitides (AAV)

- Local database of AAV in Prague since 1993
- National level & online data collection since 2009
- Main aims:
 - To obtain consistent epidemiologic and clinical data on patients with AAV in the Czech Republic
 - To support modern therapeutic strategies in (young and/or refractory) AAV patients

16 centres in 7 cities:

9x Nephrology

4x Rheumatology

2x Immunology

1x Pediatrics

Results


n = 689 patients:

Male/Female: 330/359 (48/52%)


Median age at dg: 58 (range 11 – 89) years

No of patients alive: 510 ; → Prevalence 48.5 pmp


Age distribution:




ANCA type (ever) ELISA and/or IIF



Cumulative organ involvement (n: 689)



Causes of death



2.9x increased risk of death due to cardiovascular cause,
in patients aged 15-64 years: 10x increased risk of mortality (all causes)

In morphological point of view, ANCA vasculitis should be considered when :

- *Chronic inflammation in ear and/or repeated sinusitis*
- Skin vasculitic lesions: painful
- *Ischemic ulcers in GIT*
- Pauciimmune necrotizing GN
- Lungs: *hemoptysis and changing infiltrates* („GPA“ can imitate **tumor** and older patients are sometimes treated with cytostatic drugs)
- **Unexplained chronic inflammatory disease**

Rare: PAN, Kawasaki, Takayasu

„More frequent“: GCA, drugs associated vasculitis (mainly skin lesions)

ANCA associated vasculitis is the most common form of systemic vasculitis of adults.

16th Prague Postgraduate Training Course in Nephrology and ERA-EDTA CME Course (22. – 23. 1. 2016)

Organized by CNS, ERA- EDTA immunonephrology WG, RPS, and Nephropath®

Nephropathology for the nephrologists



Introduction to renal pathology and approach to diagnosis
(clinic-pathology correlations)

When to add *molecular pathology* to the diagnosis of kidney
diseases (*Helen Liapis, US*)

Clinical up-data of membranous nephropathy: *Is it time to
change the guidelines?* (*Pierre Ronco*)



Should the patients with a clear diagnosis of AAV be
biopsied? (*V. Tesarř*)

How I treat a patient with AAV (3 case reports)

Interpretation of renal allograft biopsies: an algorithmic
approach with up-grade of Banff classification system (*A.
Perkowska-Ptasińska*)